Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 93Lymphoid 25Other hematologic neoplasm 16Genitourinary 3Sarcoma 2Breast 2Tumor-Agnostic 1Myeloid 1CNS 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ixazomib × Breast × Clear all
NCT02993094 2020-11-30

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

Arbeitsgemeinschaft medikamentoese Tumortherapie

Phase 1/2 Terminated
31 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02384746 2019-04-29

Millennium

Dartmouth-Hitchcock Medical Center

Phase 1 Terminated
9 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡